Miguel Tarón

1.3k total citations
23 papers, 889 citations indexed

About

Miguel Tarón is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Miguel Tarón has authored 23 papers receiving a total of 889 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 10 papers in Molecular Biology and 10 papers in Oncology. Recurrent topics in Miguel Tarón's work include Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (7 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Miguel Tarón is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Lung Cancer Research Studies (7 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Miguel Tarón collaborates with scholars based in Spain, United States and Poland. Miguel Tarón's co-authors include Rafael Rosell, Cristina Queralt, Bartomeu Massutí, Teresa Morán, José Javier Sánchez, José Miguel Sánchez, Lurdes Zamora, Tony Mok, Christian Manegold and Victor Hsue and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and European Respiratory Journal.

In The Last Decade

Miguel Tarón

21 papers receiving 864 citations

Peers

Miguel Tarón

PRM

ONCOL

SURGE

Giovanni Palazzolo Italy

Pil Gyu Hwang South Korea

Tejas Patil United States

Xuezhi Hao China

Hidenobu Ishii Japan

F. Gamza United States

Antonella Flacco Italy

Alberto Cambieri Italy

Jinpeng Shi China

Giovanni Palazzolo Italy

Miguel Tarón

474 ×0.7

PRM

528 ×0.9

ONCOL

211 ×0.9

85 ×0.5

42 ×0.8

SURGE

Citations per year, relative to Miguel Tarón Miguel Tarón (= 1×) peers Giovanni Palazzolo

Countries citing papers authored by Miguel Tarón

Since Specialization

Citations

This map shows the geographic impact of Miguel Tarón's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Miguel Tarón with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Miguel Tarón more than expected).

Fields of papers citing papers by Miguel Tarón

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Miguel Tarón. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Miguel Tarón. The network helps show where Miguel Tarón may publish in the future.

Co-authorship network of co-authors of Miguel Tarón

This figure shows the co-authorship network connecting the top 25 collaborators of Miguel Tarón. A scholar is included among the top collaborators of Miguel Tarón based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Miguel Tarón. Miguel Tarón is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moura, David S., Antonio Fernández‐Serra, María López-Álvarez, et al.. (2020). CUL4A, ERCC5, and ERCC1 as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study. Cancers. 12(5). 1128–1128. 3 indexed citations

Garrigós, Carmen, Sonia Molina‐Pinelo, Miguel Tarón, et al.. (2020). MicroRNAs as potential predictors of extreme response to tyrosine kinase inhibitors in renal cell cancer. Urologic Oncology Seminars and Original Investigations. 38(7). 640.e23–640.e29. 4 indexed citations

Alemany, Regina, David S. Moura, Andrés Redondo, et al.. (2018). Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma. Clinical Cancer Research. 24(21). 5239–5249. 22 indexed citations

Garrigós, Carmen, Ana Salinas, R.A. Medina López, et al.. (2017). Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinoma. Oncotarget. 8(63). 106551–106564. 17 indexed citations

Bover, Isabel, Christian Rolfo, Eloísa Jantus‐Lewintre, et al.. (2011). Fifth Educational Symposium of the Spanish Lung Cancer Group: Report on the Molecular Biology Workshop. Lung Cancer. 74(3). 535–543.

Schöffski, Patrick, Miguel Tarón, José Jimeno, et al.. (2011). Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study. European Journal of Cancer. 47(7). 1006–1012. 73 indexed citations

Massutí, Bartomeu, Manuel Cobo, Carlos Camps, et al.. (2011). Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum. Lung Cancer. 76(3). 354–361. 25 indexed citations

Porta, R., J.M. Sánchez-Torres, Luis Paz‐Ares, et al.. (2010). Brain metastases from lung cancer responding to erlotinib: the importance ofEGFRmutation. European Respiratory Journal. 37(3). 624–631. 247 indexed citations

Simonetti, Sonia, Matias Molina, Clara Mayo, et al.. (2010). Immunohistochemistry (IHC) with EGFR mutation-specific monoclonal antibodies (mAbs) for screening EGFR mutations in non-small cell lung cancer (NSCLC) patients (p).. Journal of Clinical Oncology. 28(15_suppl). 7570–7570. 1 indexed citations

10.

García-Olivé, Ignasi, Eduard Monsó, Felipe Andreo, et al.. (2009). Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations. European Respiratory Journal. 35(2). 391–395. 109 indexed citations

11.

Porta, R., Cristina Queralt, F. Cardenal, et al.. (2008). Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p). Journal of Clinical Oncology. 26(15_suppl). 8038–8038. 8 indexed citations

12.

Morán, María Teresa Cabero, Dolores Isla, Manuel Cobo, et al.. (2007). PD2-3-3: High correspondence between EGFR mutations in tissue and in circulating DNA form non-small-cell lung cancer (NSCLC) patients (p) with poor performance status (PS). Journal of Thoracic Oncology. 2(8). S444–S444. 1 indexed citations

13.

Rosell, Rafael, Ewa Jassem, Marcin Skrzypski, et al.. (2007). D5-02: Increased BRCA1 mRNA: an independent prognostic variable in completely resected chemonaive non-small-cell lung cancer (NSCLC) patients (p). Journal of Thoracic Oncology. 2(8). S403–S403. 1 indexed citations

14.

Morán, Teresa, Luis Paz‐Ares, Manuel Cobo, et al.. (2007). High correspondence between EGFR mutations in tissue and in circulating DNA form non-small-cell lung cancer (NSCLC) patients (p) with poor performance status (PS). Journal of Clinical Oncology. 25(18_suppl). 7505–7505. 11 indexed citations

15.

Ramírez, José Luis, J. R. P. Gupta, Miguel Tarón, et al.. (2006). Methylation Patterns and Chemosensitivity in NSCLC. Advances in experimental medicine and biology. 587. 195–209. 4 indexed citations

16.

Rosell, Rafael, Teresa Morán, Pedro Méndez, et al.. (2006). The place of targeted therapies in the management of non-small cell bronchial carcinoma. Revue des Maladies Respiratoires. 23(5). 131–136. 6 indexed citations

17.

Rosell, Rafael, Miguel Tarón, Giuseppe Altavilla, & Mariacarmela Santarpía. (2005). Chemotherapy Treatment Options for Non-small-cell Lung Cancer. European Oncology & Haematology. 1–1. 1 indexed citations

18.

Tarón, Miguel, Yukito Ichinose, Rafael Rosell, et al.. (2005). Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas. Clinical Cancer Research. 11(16). 5878–5885. 280 indexed citations

19.

Tarón, Miguel, Rafael Rosell, John Souglakos, et al.. (2004). BRCA1 and HIF-1α mRNA expression and chemoresistance in non-small-cell lung cancer (NSCLC). Journal of Clinical Oncology. 22(14_suppl). 7148–7148. 1 indexed citations

20.

Camps, Carlos, Bárbara Roig, José Javier Sánchez, et al.. (2003). Assessment of Nucleotide Excision Repair XPD Polymorphisms in the Peripheral Blood of Gemcitabine/Cisplatin–Treated Advanced Non–Small-Cell Lung Cancer Patients. Clinical Lung Cancer. 4(4). 237–241. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact